Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences

THE WOODLANDS, Texas, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management will present at three upcoming investor conferences

GlobeNewswireSep 2 04:05

Lexicon Pharmaceuticals Says Post Hoc Analysis Of Phase 3 SOLOIST-WHF Trial Shows Sotagliflozin Reduced Cardiovascular Deaths, Heart Failure Events Regardless Of Baseline Systolic Blood Pressure, Without Increase In Hypotension Or Acute Kidney Injury

Lexicon Pharmaceuticals Says Post Hoc Analysis Of Phase 3 SOLOIST-WHF Trial Shows Sotagliflozin Reduced Cardiovascular Deaths, Heart Failure Events Regardless Of Baseline Systolic Blood Pressure,

BenzingaAug 31 20:32

Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)

TipRanksAug 24 22:50

Lexicon Earns Third $10M Novo Milestone

Seeking AlphaAug 24 20:42

Express News | Lexicon Pharmaceuticals, - Eligible for up to $1 Bln in Upfront and Milestone Payments Plus Royalties

BreakingsAug 24 20:30

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment From Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1

GlobeNewswireAug 24 20:30